Kala Pharmaceuticals Inc (KALA)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

490 ARSENAL WAY WATERTOWN, MA 02472

Kala Pharmaceuticals, Inc. develops pharmaceutical formulations. The Company designs proprietary drug delivery technology to penetrate mucosal tissue such as the eyes, lungs, gastrointestinal tracts, and the female reproductive systems. Kala Pharmaceuticals markets its products worldwide.

Data as of 2020-08-01
Market Cap487.514 Million Shares Outstanding55.716 Million Avg 30-day Volume1.018 Million
P/E Ratio Dividend Yield EPS-2.76
Price/Sales Price cash flow ratio Price free cash flow ratio-3.1
Book Value0.81 Price to Tangible Book9.83 Alpha-0.0
Short Interest Ratio % Short Interest to Float R-squared0.002308
BETA0.228792 52-week High/Low14.68 / 3.24 Stddev0.235988
View SEC Filings from KALA instead.
Q1 2020 All Institutions Hedge Funds 1
Filers who had this stock in their top 10: 2 0 (0.0%)
13F Filers holding this stock: 96 35 (2.29%)
Aggregate 13F shares on 03/31/2020: 40.139 Million 27.885 Million
Aggregate 13F shares on 12/31/2019: 22.913 Million 14.741 Million
Percent change: 75.18% 89.17%
Funds creating new positions: 40 17
Funds Adding to an existing position: 27 11
Funds closing out their position: 12 6
Funds reducing their position: 16 5
1 hedge funds as identified by whalewisdom.com through public filings.

View recent insider trading info

Funds Holding KALA (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding KALA BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

28.9 Thousand total shares from 1 transactions

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

GRUNBERG GREGORY

  • Director
  • 10% Owner
2,600,877 2020-07-10 2

IWICKI MARK T

  • Director
0 2020-06-30 2

PERRY GREGORY D

  • Director
0 2020-06-30 1

TEPPER ROBERT I

  • Director
  • 10% Owner
0 2020-06-26 0

SHAH RAJEEV M.

  • Director
  • 10% Owner
10,894,613 2020-06-25 2

ROSEN HOWARD B

  • Director
33,064 2020-06-25 2

REUMUTH MARY CHIEF FINANCIAL OFFICER

  • Officer
64,293 2020-06-25 3

BRAZZELL ROMULUS K CHIEF MEDICAL OFFICER

  • Officer
195,496 2020-06-25 3

PAULL ROBERT BRADLEY

  • Director
22,361 2020-06-25 1

CHEN HONGMING CHIEF SCIENTIFIC OFFICER

  • Officer
102,849 2020-06-25 3

KOVEN ANDREW I

  • Director
28,000 2020-06-25 1

BAZEMORE TODD CHIEF OPERATING OFFICER

  • Officer
29,000 2020-06-25 4

TRACHTENBERG ERIC SEE REMARKS

  • Officer
44,901 2020-06-25 4

LONGITUDE CAPITAL PARTNERS II, LLC

LONGITUDE VENTURE PARTNERS II, L.P.

ENRIGHT PATRICK G

TAMMENOMS BAKKER JULIET

  • 10% Owner
0 2020-06-11 0

LANGER ROBERT

  • Director
0 2020-06-11 0

MCDERMOTT CHARLES DOUGLAS

  • Director
0 2020-05-28 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP VI LLC

  • Director
  • 10% Owner
2,765,717 2020-04-24 0

RA CAPITAL MANAGEMENT, L.P.

RA CAPITAL HEALTHCARE FUND LP

KOLCHINSKY PETER

  • Director
  • 10% Owner
0 2020-04-02 1

HADLEY HARBOR MASTER INVESTORS (CAYMAN) L.P.

  • 10% Owner
4,962,678 2020-03-24 0

POLARIS VENTURE MANAGEMENT CO. V, L.L.C.

POLARIS VENTURE PARTNERS V, L.P.

POLARIS VENTURE PARTNERS ENTREPRENEURS' FUND V, L.P.

POLARIS VENTURE PARTNERS FOUNDERS' FUND V, L.P.

POLARIS VENTURE PARTNERS SPECIAL FOUNDERS' FUND V, L.P.

  • 10% Owner
6,702,399 2019-07-15 0

CDK ASSOCIATES, L.L.C.

CAXTON CORP

KOVNER BRUCE

  • 10% Owner
6,581,305 2018-12-26 0

HILL PAULINA

  • Director
0 2018-07-02 0

LARUSSA MICHELE SR. VP, REGULATORY AND QUALITY

  • Officer
0 2018-02-07 0

ORBIMED ADVISORS LLC

ORBIMED CAPITAL GP VI LLC

ISALY SAMUEL D

  • 10% Owner
2,452,231 2018-01-10 0

CVF, LLC

  • 10% Owner
0 2017-07-19 0

YSIOS BIOFUND I FCR

  • 10% Owner
0 2017-07-19 0

LUX CAPITAL MANAGEMENT, LLC

LUX VENTURE ASSOCIATES II, LLC

LUX VENTURE PARTNERS II, L.P.

LUX VENTURES II SIDECAR LP

LUX VENTURES II, L.P.

  • 10% Owner
0 2017-07-19 0

HANES JUSTIN

  • 10% Owner
601,923 2017-07-19 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5

ROSEN HOWARD B - Director

2020-06-25 A 20,000 a 24,824 33,064.00 direct

GRUNBERG GREGORY - Director

2020-06-25 A 20,000 a 20,000 5,431,860.00 direct

CHEN HONGMING - Officer CHIEF SCIENTIFIC OFFICER

2020-06-25 A 16,000 a 102,849 102,849.00 direct

REUMUTH MARY - Officer CHIEF FINANCIAL OFFICER

2020-06-25 A 16,000 a 64,293 64,293.00 direct

PAULL ROBERT BRADLEY - Director

2020-06-25 A 20,000 a 20,000 22,361.00 direct

PERRY GREGORY D - Director

2020-06-25 A 20,000 a 20,000 20,000.00 direct

BRAZZELL ROMULUS K - Officer CHIEF MEDICAL OFFICER

2020-06-25 A 19,000 a 195,496 195,496.00 direct

BAZEMORE TODD - Officer CHIEF OPERATING OFFICER

2020-06-25 A 19,000 a 29,000 29,000.00 direct

IWICKI MARK T - Director - Officer CHIEF EXECUTIVE OFFICER

2020-06-25 A 49,560 a 49,560 49,560.00 direct

TRACHTENBERG ERIC - Officer SEE REMARKS

2020-06-25 A 16,000 a 44,901 44,901.00 direct

KOVEN ANDREW I - Director

2020-06-25 A 28,000 a 28,000 28,000.00 direct

SHAH RAJEEV M. - Director - > 10% Owner

2020-06-25 A 20,000 a 20,000 10,894,613.00 direct

TRACHTENBERG ERIC - Officer SEE REMARKS

2020-06-19 M 28,901 $5.19 a 28,901 28,901.00 direct

TRACHTENBERG ERIC - Officer SEE REMARKS

2020-06-19 M 28,901 d 136,099 28,901.00 direct
Transaction Code Definitions
Code Definition
A Grant, award or other acquisition pursuant to Rule 16b-3(d)
C Conversion of derivative security
D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
E Expiration of short derivative position
F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
G Bona fide gift
H Expiration (or cancellation) of long derivative position with value received
I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
J Other acquisition or disposition
L Small acquisition under Rule 16a-6
M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
O Exercise of out-of-the-money derivative security
P Open market or private purchase of non-derivative or derivative security
S Open market or private sale of non-derivative or derivative security
U Disposition pursuant to a tender of shares in a change of control transaction
W Acquisition or disposition by will or the laws of descent and distribution
X Exercise of in-the-money or at-the-money derivative security
Z Deposit into or withdrawal from voting trust

Elevate your investments